$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
Large ischemic stroke is one of the major causes of morbidity and disability worldwide1. Still, mouse stroke research faces a translational block in almost all preclinically tested treatments so far2. The multiple reasons for this problem and the efforts to overcome it have been reviewed in detail in previous publication2. These challenges arise from the limited integration of clinical advances into relevant animal models2 and the weaknesses of behavioral and neurological scoring systems in detecting post-stroke deficits accurately and sensitively2.
Recent discoveries3 support that the filament model of middle artery occlusion (fMCAo) in mice has significant translational advantages over other models with open skull injury and trauma2,4. On top of that, this is the only one that models the reperfusion and mechanical thrombectomy of clinical stroke settings5,6,7. However, the model faces high subacute mortality between 3-7 days post-stroke, which prohibits long-term studies of large strokes and was considered until recently the model´s inherent and insurmountable artifact. In addition, the detection of post-stroke neurological deficits is relatively difficult and biased in mice due to their small size, especially among non-clinicians or inexperienced researchers8,9. To address this, different groups have developed various scales to detect deficits. The most used and known scales include the 3-point Bederson scale (BS)10, the 5-point modified Bederson scale (mBS)11, the 5-point Longa score (LS) (which is similar to mBS)6, the modified Neurological Stroke Scale (mNSS)12,13, the 18-point Garcia scale (GS)9 and the more detailed DeSimoni14 or differently known as "Neuroscore" (NS)9,15 scale. Unfortunately, some of these scales are either too crude and are restricted only to the few acute-phase days following stroke (BS, mBS and LS)8,9 or their interpretation is blurred by general deficits (NS).
With this background, we previously developed and validated the mouse Stroke Unit (mSU) support protocol, along with the experimental stroke scale (ESS) for mice13. The rationale for mSU was to adapt knowledge from the clinical routine (i.e., human stroke units) into preclinical research of stroke, while ESS critically consolidated previously existing but "insensitive" or redundant stroke scales into a practical, refined, sensitive and time-efficient one. The mSU consists of frequent and adapted monitoring of mouse´s basic clinical parameters with adapted application of animal support to enhance survival13.
Indeed, data from our laboratory and others verify the value of both methods. The mSU translates clinical basic supportive measures and advances7 from humans to mice, significantly reduces mortality of the fMCAo in mice from 60-70% to 10-15%13 thus allowing for studies of larger strokes, and can be effectively applied in independent laboratories since then16,17,18,19. In addition, the ESS can distinguish between focal (focal component of ESS, fESS) and general (general component of ESS, gESS) post-stroke deficits and symptoms, models the human clinical scoring (differentiation between focal and general signs and symptoms in humans), is linearly related to the stroke lesion size and is long-term sensitive to deficits13,20. Still, despite the proven value and efficacy of both mSU and ESS, the lack of clear-cut, visualized, standardized instructions for even inexperienced researchers leaves several open questions on mSU application and significant subjectivity on scoring focal deficits on fESS.
As such, our present article aims to provide video-assisted and clear instructions for mSU and fESS protocols. We strongly believe that it will support stroke researchers to increase the translational efficiency of their stroke studies, significantly reduce the loss of animals during the first 3-10 days after stroke, reduce experimentation costs, and eventually reproducibly evaluate neurological deficits for months after stroke13. Additionally, the add-on combination of the Ladder-rung test and Cylinder test can easily quantify the focal limb paresis (fore- and hindlimbs) due to fMCAo.
To showcase mSU and fESS efficiency, we provide medium- (14-days) and long-term (6-month) data on mice after fMCAo. Twelve-week-old male C57Bl/6J mice (n= 31) were used and housed under controlled temperature (22 ± 2 °C), with a 12 h light-dark cycle period and access to pelleted food and water ad libitum. Mice were divided into two cohorts followed for 14 days (n=10, cohort 1) and 6 months (n=15, cohort 2) respectively. These mice were subjected to a 60 min cerebral ischemia using the well-described model of fMCAo13,20,21 under isoflurane anesthesia. Sham-operated animals (n=6, operated as the above two cohorts, but no ischemia was induced) followed for 6 months served as controls. Buprenorphine was used as a pre- and 3-day post-operative analgesic. The Ladder rung and cylinder tests were also performed for the 6-month cohort as a part of the neurological scoring.
All animals were checked daily for humane endpoints during the first 14 days post-stoke, defined as: 1) severe hypothermia (<33 °C) and/or immobility (e.g., score 4 on Test 6 of fESS or "spontaneous activity" test of gESS) that was not improved by "mouse Stroke Unit" treatment (i.e., passive heating and active feeding, see 1.4, 1.6, 1.8) within one hour, 2) signs of pain or anxiety behavior (e.g. score >2 in "anxiety/automatic behavior" test of gESS), even after post-operative analgesia as per the protocol.
In this protocol, post-stroke support of the mice in the form of mSU begins immediately after mouse recovery from the fMCAo operation. This has 3 phases: phase A (0-48 h post-reperfusion), phase B (>48 h and up to the "end of needed active support", usually at day 10-14, depending on individual animal´s phase B), and phase C (day 14 onwards). It has five significant interventions (visits/Risk Stratification Score, feeding, fluids, temperature, and local disinfections; see 1.1. to 1.8. below) tailored to each animal, according to each phase (A, B or C) and its daily actual clinical status assessed by the Risk Stratification Score (RSS), see Supplementary Figure 1 and Table 1 with three typical examples. The required materials and tools for mSU are shown in Figure 1a and described in Table of Materials. We also provide a template for animal monitoring during mSU (see Supplementary File 1).